Hepatotoxicity of New Oral Anticoagulants (NOACs)

Drug Safety

38, 711-720

DOI: 10.1007/s40264-015-0317-5

Citation Report

#	Article	IF	Citations
1	Apixaban-induced liver injury. BMJ Case Reports, 2016, 2016, bcr2016216744.	0.2	11
2	Drug-Induced Liver Injury. AACN Advanced Critical Care, 2016, 27, 430-440.	0.6	29
3	Rivaroxaban induced liver injury: A cholestatic pattern. International Journal of Cardiology, 2016, 216, 97-98.	0.8	11
4	Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Safety, 2016, 39, 801-821.	1.4	74
5	Riskâ€“Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Safety, 2016, 39, 1175-1187.	1.4	31
7	Apixaban-induced hepatotoxicity. International Journal of Cardiology, 2016, 204, 4-5.	0.8	14
8	Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. British Journal of Clinical Pharmacology, 2017, 83, 1532-1543.	1.1	34
9	Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart, 2017, 103, 834-839.	1.2	57
10	Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs. Drug Safety, 2017, 40, 1091-1098.	1.4	15
11	Drug Hepatotoxicity. Clinics in Liver Disease, 2017, 21, 115-134.	1.0	58
12	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	1.9	178
13	Non-hemorrhage-related adverse effects of rivaroxaban. Archives of Medical Sciences Atherosclerotic Diseases, 2017, 2, 108-112.	0.5	14
14	Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions. Current Drug Metabolism, 2017, 18, 609-621.	0.7	23
15	Drug-induced liver injury: Towards early prediction and risk stratification. World Journal of Hepatology, 2017, 9, 30.	0.8	22
16	Nonâ€“Vitamin K Antagonist OralÂAnticoagulants and RiskÂofÂSeriousÂLiver Injury. Journal of the American College of Cardiology, 2018, 71, 1105-1113.	1.2	36
17	Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis. Drug Safety, 2018, 41, 881-897.	1.4	28
18	Liver disease and heart failure: Back and forth. European Journal of Internal Medicine, 2018, 48, 25-34.	1.0	53
19	Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 1-5.	0.6	9

#	Article	IF	Citations
20	Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. European Journal of Gastroenterology and Hepatology, 2018, 30, 226-232.	0.8	33
21	A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge. Journal of Clinical Medicine Research, 2018, 10, 523-526.	0.6	6
22	Development and validation of chromatographic methods for the quantification of dabigatran etexilate mesylate in the presence of its risky degradation products. Journal of Planar Chromatography - Modern TLC, 2018, 31, 461-468.	0.6	1
23	Hepatotoxicity of New Oral Anticoagulants. Rational Pharmacotherapy in Cardiology, 2018, 14, 621-628.	0.3	0
24	Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. International Journal of Hepatology, 2018, 2018, 1-9.	0.4	66
25	Apixaban-induced fatal liver injury with a cholestatic pattern. European Journal of Internal Medicine, 2019, 70, e17-e18.	1.0	4
26	Direct Oral Anticoagulants in Chronic Liver Disease. Annals of Pharmacotherapy, 2019, 53, 1042-1049.	0.9	32
27	Cadmium and Fullerenes in Liver Diseases. , 2019, , 333-344.		5
28	Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Safety, 2019, 42, 365-387.	1.4	82
29	Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study. Scientific Reports, 2020, 10, 11624.	1.6	10
30	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. American Journal of Gastroenterology, 2020, 115, 1513-1524.	0.2	9
31	Liver injury caused by oral anticoagulants: A populationâ€based retrospective cohort study. Liver International, 2020, 40, 1895-1900.	1.9	15
32	Realâ€world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A metaâ€analysis. Clinical Cardiology, 2020, 43, 676-683.	0.7	5
33	Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant. Cardiovascular Drugs and Therapy, 2022, 36, 121-129.	1.3	12
34	Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. European Journal of Clinical Pharmacology, 2021, 77, 1073-1076.	0.8	4
35	Low rates of liver injury in edoxaban users: Evidence from a territoryâ€wide observational cohort study. Clinical Cardiology, 2021, 44, 886-889.	0.7	4
36	Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase. Journal of Personalized Medicine, 2021, 11, 250.	1.1	9
37	Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1027-1040.	0.7	6

#	Article	IF	Citations
38	Acute liver failure after changing oral anticoagulant from apixaban to rivaroxaban. BMJ Case Reports, 2021, 14, e240719.	0.2	5
39	Reply to: Liver injury caused by oral anticoagulants: A populationâ€based retrospective cohort study. Liver International, 2021, 41, 1435-1436.	1.9	1
40	Dabigatran-induced acute liver injury in older patients: case report and literature review. Journal of Gerontology and Geriatrics, 2021, 69, 221-225.	0.2	1
41	Safety and interaction of direct oral anticoagulants with antiarrhythmic drugs. Russian Journal of Cardiology, 2021, 26, 4482.	0.4	0
42	Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Safety, 2021, 44, 1125-1149.	1.4	35
43	Dual mechanisms suppress meloxicam bioactivation relative to sudoxicam. Toxicology, 2020, 440, 152478.	2.0	16
44	Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. PLoS ONE, 2016, 11, e0155337.	1.1	11
45	A Case of Liver Failure Due to Dabigatran Treated with Venovenous Hemodiafiltration and Idarucizumab. Current Drug Safety, 2020, 15, 227-230.	0.3	6
46	Direct oral anticoagulants: a guide for daily practice. Swiss Medical Weekly, 2016, 146, w14286.	0.8	11
47	Rivaroxaban: comparative analysis of information on adverse reactions from Russian and international databases. Klinicheskaia Meditsina, 2017, 95, 451-456.	0.2	0
48	Gastro-duodenal risks during therapy with new oral anticoagulants and possibility of minimizing them. Medical Alphabet, 2020, , 26-32.	0.0	0
49	NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2021, 57, .	0.4	1
50	Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence?. World Journal of Hepatology, 2022, 14, 682-695.	0.8	5
51	Use of Newer Anticoagulants in Patients with Cirrhosis. Current Hepatology Reports, 2022, 21, 45-51.	0.4	1
52	Oral Anticoagulation in Patients with Chronic Liver Disease. Medicina (Lithuania), 2023, 59, 346.	0.8	3